CENTURY THERAPEUTICS INC (IPSC) Stock Price, Forecast & Analysis
NASDAQ:IPSC • US15673T1007
IPSC Key Statistics, Chart & Performance
The current stock price of IPSC is 2.14 USD. In the past month the price increased by 4.9%. In the past year, price increased by 193.11%.
IPSC Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to IPSC. When comparing the yearly performance of all stocks, IPSC is one of the better performing stocks in the market, outperforming 99.4% of all stocks.
IPSC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IPSC. While IPSC has a great health rating, there are worries on its profitability.
IPSC Financial Highlights
Over the last trailing twelve months IPSC reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS increased by 87.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -10.82% | ||
| ROE | -15.01% | ||
| Debt/Equity | 0 |
IPSC Forecast & Estimates
11 analysts have analysed IPSC and the average price target is 4.2 USD. This implies a price increase of 96.37% is expected in the next year compared to the current price of 2.14.
For the next year, analysts expect an EPS growth of 91.66% and a revenue growth 3161.86% for IPSC
IPSC Ownership
IPSC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.45 | 396.512B | ||
| AMGN | AMGEN INC | 16.66 | 202.199B | ||
| GILD | GILEAD SCIENCES INC | 16.94 | 187.492B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.02 | 119.063B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.84 | 82.713B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.66 | 44.834B | ||
| INSM | INSMED INC | N/A | 34.336B | ||
| NTRA | NATERA INC | N/A | 30.104B | ||
| BIIB | BIOGEN INC | 12.63 | 28.19B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.31 | 20.691B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IPSC
Company Profile
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 140 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The firm has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
Company Info
CENTURY THERAPEUTICS INC
25 N 38Th Street, 11Th Floor
PHILADELPHIA PENNSYLVANIA US
CEO: Osvaldo Flores
Employees: 140
Phone: 12159814000
CENTURY THERAPEUTICS INC / IPSC FAQ
What does IPSC do?
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 140 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The firm has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.
Can you provide the latest stock price for CENTURY THERAPEUTICS INC?
The current stock price of IPSC is 2.14 USD. The price increased by 1.9% in the last trading session.
Does CENTURY THERAPEUTICS INC pay dividends?
IPSC does not pay a dividend.
What is the ChartMill rating of CENTURY THERAPEUTICS INC stock?
IPSC has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is IPSC stock listed?
IPSC stock is listed on the Nasdaq exchange.
Would investing in CENTURY THERAPEUTICS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IPSC.
Can you provide the ownership details for IPSC stock?
You can find the ownership structure of CENTURY THERAPEUTICS INC (IPSC) on the Ownership tab.